Gilead has touted the potential of its liver disease drug in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication.
The survey was conducted by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Kidney disease risk higher after Covid infection than after influenza infection
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Biorce secures $52.5m in Series A to expand AI clinical trial tech